Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acs.jmedchem.0c00502 http://scihub22266oqcxt.onion/10.1021/acs.jmedchem.0c00502 32539378!7315836!32539378     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Med+Chem 2020 ; 63 (21): 12256-12274 Nephropedia Template TP {{tp|p=32539378|t=2020. Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities |pdf=|usr=}}{{32539378}} gab.com Text Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities JO: J Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32539378 #FOAvip Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of "coronavirus disease 2019", abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific prophylactic or postexposure therapy for COVID-19 are currently available. Viral entry is the first step in the SARS-CoV-2 lifecycle and is mediated by the trimeric spike protein. Being the first stage in infection, entry of SARS-CoV-2 into host cells is an extremely attractive therapeutic intervention point. Within this review, we highlight therapeutic intervention strategies for anti-SARS-CoV, MERS-CoV, and other coronaviruses and speculate upon future directions for SARS-CoV-2 entry inhibitor designs. Twit Text FOAVip Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities ????J Med Chem http://www.kidney.de/pget.php?&tw=1&pmid=32539378 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32539378 #FOAvip English Wikipedia <ref>{{Cite pmid|32539378}}</ref> Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities #MMPMID32539378 Xiu S; Dick A; Ju H; Mirzaie S; Abdi F; Cocklin S; Zhan P; Liu X J Med Chem 2020[Nov]; 63 (21): 12256-12274 PMID32539378show ga Recently, a novel coronavirus initially designated 2019-nCoV but now termed SARS-CoV-2 has emerged and raised global concerns due to its virulence. SARS-CoV-2 is the etiological agent of "coronavirus disease 2019", abbreviated to COVID-19, which despite only being identified at the very end of 2019, has now been classified as a pandemic by the World Health Organization (WHO). At this time, no specific prophylactic or postexposure therapy for COVID-19 are currently available. Viral entry is the first step in the SARS-CoV-2 lifecycle and is mediated by the trimeric spike protein. Being the first stage in infection, entry of SARS-CoV-2 into host cells is an extremely attractive therapeutic intervention point. Within this review, we highlight therapeutic intervention strategies for anti-SARS-CoV, MERS-CoV, and other coronaviruses and speculate upon future directions for SARS-CoV-2 entry inhibitor designs. |*COVID-19 Drug Treatment[MESH] |Amino Acid Sequence[MESH] |Angiotensin-Converting Enzyme 2/chemistry/metabolism[MESH] |Angiotensin-Converting Enzyme Inhibitors/therapeutic use[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/prevention & control[MESH] |Cathepsin L/antagonists & inhibitors[MESH] |Cell Line[MESH] |Humans[MESH] |Protein Domains[MESH] |SARS-CoV-2/*drug effects[MESH] |Spike Glycoprotein, Coronavirus/antagonists & inhibitors[MESH]Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities (epmc).pdf DeepDyve Pubget Overpricing